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ABSTRACT 
Objective. The aim of this study was to identify the clinical features that can help to 
distinguish between psoriatic arthritis (PsA) and fibromyalgia (FM). 
Methods. This multicentre cross-sectional study was carried out in ten Italian 
rheumatological centres between January and September 2009, and enrolled all of the 
consecutive PsA and FM patients who agreed to participate. All of the standard clinical 
and laboratory data for PsA and FM were collected from all of the patients, and their 
somatic symptoms, response to non-steroidal anti-inflammatory drugs (NSAIDs), self-
evaluated pain, general health, disability and responses to the Fibromyalgia Impact 
Questionnaire were recorded. The data were statistically analysed by means of univariate 
and multivariate analyses, and receiver operating characteristic curves. Given the purpose 
of the study, the analysis concentrated on the clinical features shared by the two 
conditions. 
Results. Two hundred and sixty-six PsA patients (mean age 51.7 years; disease duration 
10.2 years) and 120 FM patients (mean age 50.2 years; disease duration 5.6 years) were 
evaluated. Univariate analysis showed that the FM patients had higher mean tender point 
and enthesitic scores, more somatic symptoms, and responded less to NSAIDs. 
Multivariate analysis showed that the presence of 6 FM-associated symptoms and 8 or 
more tender points were the best predictors of FM. 
Conclusion. The shared clinical features of PsA and FM that had the greatest 
discriminating power for FM were the number of FM-associated symptoms and tender 
point count. 
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INTRODUCTION 
Fibromyalgia (FM) is a common cause of chronic widespread pain (CWP) and often 
responsible for rheumatologic consultations. Its prevalence in the general adult general 
population is about 2%, but considerably different between males and females (about 
0.5% vs about 3.5%) [1,2]. According to the 1990 ACR criteria [3], a diagnosis of FM 
requires the presence of CWP and tenderness in at least 11 out of 18 tender points when 
applying a pressure of 5 kg. A new set of criteria has recently been proposed by the ACR 
[4] that does not require a tender point examination but includes a subjective measure of 
the number of painful body regions and a somatic symptom severity scale. In association 
with CWP, somatic symptoms such as fatigue, headache, irritable bowel syndrome, sleep 
disturbances, paresthesias, muscle weakness, bladder dysfunction, depression, anxiety, 
Raynaud’s phenomenon and many others are typical features of FM, and the constellation 
of symptoms is such that the disease is usually easily recognised by physicians. However, 
diagnostic difficulties may arise in case of CWP due to condition other than FM.  
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disorder belonging to 
the heterogeneous group of spondyloarthropathies (SpAs), and can affect up to 30% of 
patients with psoriasis [5]. It is a protean disease that involves the entheses, joints, 
tendons and bones of both the peripheral and axial skeleton. Enthesitis can be very 
difficult to diagnose because its symptoms and signs may be aspecific and relatively 
indistinguishable from those of FM. Patients with primary FM and psoriasis or FM 
associated with PsA and those with psoriatic polyenthesitis may have almost identical 
clinical features and are at risk of misdiagnosis and management errors. 
The aim of this study was to identify which clinical features recorded during a standard 
rheumatological evaluation might help to distinguish PsA and FM. 
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PATIENTS AND METHODS 
Study design 
This multicentre, cross-sectional study was carried out by 10 Italian tertiary 
rheumatological centres between January and September 2009: seven Centres 
specialised in PsA enrolled only PsA patients, two specialised in FM enrolled only FM 
patients, and one enrolled both PsA and FM patients. All of the patients were asked for 
their informed consent to participate to the study. 
Inclusion and exclusion criteria, and clinical evaluation 
The inclusion criteria were a diagnosis of PsA or FM according to the CASPAR [6] and 
1990 ACR criteria [3], and patient consent to participate. All of the consecutive adult 
patients aged ≥18 years attending the clinics for routine examinations during the nine-
month study period who met the inclusion criteria were enrolled. They were all receiving 
current standard levels of care for PsA and FM, and none was involved in any 
interventional research protocol at the time. In addition, eligible FM patients could not have 
a diagnosis or family history of PsA or psoriasis. 
The study centres were provided with a paper or electronic case report form (CRF) 
prepared by the coordinating centre (the Department of Rheumatology of the G. Pini 
Orthopedic Institute in Milan) for anonymous data collection. The CRF included a patient 
history, self-assessment questionnaires, and the findings of physical examinations and 
laboratory investigations. The history included the time since the onset of the first 
symptom, the familial and personal history of psoriasis, the presence of inflammatory back 
pain (IBP) as defined by Calin’s criteria [7], the history of nine FM-related 
conditions/symptoms (fatigue, headache, irritable bowel syndrome, sleep disturbances, 
paresthesias, anxiety, depression, and Raynaud’s phenomenon) apparently not due to 
other underlying conditions, and graded responsiveness (very good, good, slight and 
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none) to non-steroidal anti-inflammatory drugs (NSAIDs). The questionnaires were the 
Italian versions of the Disability Index of the Health Assessment Questionnaire (HAQ) [8], 
the Fibromyalgia Impact Questionnaire (FIQ) [9], and the Leeds Disability Questionnaire 
(LDQ) [10]. The patients were also asked to self-assess their pain and general health 
using a 100-mm visual analogue scale (VAS). The physical examinations included routine 
anthropometry, swollen and tender 66/68 joint counts, the number of irreversibly damaged 
joints (defined as those with irreversible deformities and/or at least a 30% reduction in the 
normal range of movement due to anatomic changes), pressure on the sacro-iliac joints to 
elicit pain, tender point counts, the Maastricth Ankylosing Spondylitis Enthesitis Score 
(MASES) [11], the number of digits with dactylitis, the Psoriasis Activity and Severity Index 
(PASI) [12] for skin involvement, and the number of nails with psoriatic changes. The 
pattern of articular involvement was established using the cumulative number of affected 
joints, meaning all of the joints involved at the time of the study evaluation or documented 
by a competent examiner on a previous occasion. The erythrocyte sedimentation rate 
(ESR) (Westergren method) (n.v. <15 mm/h) and C-reactive protein (CRP) levels (n.v. <1 
mg/dl) were the required laboratory tests. In order to reduce inter-observer variability in the 
tender point and entheseal site examinations, a DVD was distributed to all of the centres 
showing how to perform these examinations. We chose the MASES, rather than other 
more comprehensive enthesitis scores, because it was the instrument all of the 
investigators were most confident with. However, the following entheseal site was also 
examined: lateral and medial epicondyles, greater trochanters, quadriceps tendons, and 
plantar fascia insertions. 
The enthesis involvement was also evaluated by ultrasonography (US) in a subgroup of 30 
PsA and 30 FM patients, all from the coordinating centre. The Power Doppler Ultrasound 
(PDUS) investigation was performed by a rheumatologist with extensive experience in US, 
using a Logiq5 (General Electrics Medical Systems, Milwaukee, WI) machine equipped 
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with a broadband high-frequency (8-15 MHz) transducer, and adopting a standardized 
methodology [13]. The following entheseal sites were examined bilaterally: common 
extensor tendon at its insertion at the lateral humeral epicondyle, gluteus tendon at their 
insertion at the greater trochanter, quadriceps tendon at its insertion at the superior pole of 
the patella, patellar tendon at its proximal insertion at the inferior pole of the patella, 
patellar tendon at its distal insertion at the tibial tuberosity, Achilles tendon at its insertion 
at the calcaneus, plantar aponeurosis at its insertion at the calcaneus. According to the 
Outcome Measures in Rheumatology Clinical Trials (OMERACT) definitions of 
enthesopathy, the following changes were registered [14]: tendon hypoechogenicity at its 
bony insertion, tendon thickening at its bony insertion, intra-tendinous calcifications, 
enthesophytes, bony erosions, bony cortex irregularities, presence of Doppler signal at the 
bony insertion. 
The coordinating centre collected the CRFs from all of the centres and controlled the 
quality of the data (asking for clarifications of any missing or doubtful data), created the 
final electronic database, cleaned the final data, and carried out the data analysis. 
Statistical analysis 
The descriptive statistics included the mean values and standard deviations (SD) of the 
continuous variables, and the percentages and proportions of the categorical variables. 
The univariate analyses were made using Student’s t test, the χ2 test or Fisher’s exact test, 
and Pearson's correlation test as appropriate. The multivariate logistic regression analysis 
yielded the odds ratios (ORs) and 95% confidence intervals (95% CIs) for the risk of 
having FM rather than PsA for each variable. 
As the primary study objective was to identify which of the clinical parameters of PsA were 
more indicative of FM, only the FM-related features shared by both conditions were 
analysed in greater detail. Accordingly, in the case of tender point counts, MASES scores 
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and the presence of somatic symptoms (the most critical continuous variables 
discriminating the two conditions), the most sensitive and specific cut-off points in favour of 
FM were sought using receiver operating characteristic (ROC) curves. Similarly, the 
multivariate analysis only considered the clinical manifestations common to both 
conditions and most important for the differential diagnosis. 
As the PsA patients belonging to the “enthesitis predominant” or oligoarticular subgroups 
and those without psoriasis could be the most difficult to distinguish from FM, we analysed 
them separately. 
Given the small number of cases, no statistical analysis was performed for the PDUS data. 
For all of the analyses, a p value of 0.05 was considered statistically significant. The data 
were analysed using SPSS© software for Windows© (release 12.0, SPSS Inc., Chicago, 
USA), version 17.0. 
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RESULTS 
A total of 401 patients were enrolled but nine PsA patients were excluded because of 
missing data and six FM patients because of the presence of dactylitis, a feature too much 
indicative of SpA. Of the remaining 386 patients, 266 had PsA (125 females and 141 
males) and 120 had FM (114 females and six males); the female/male ratio was 0.89 for 
PsA and 19 for FM. Mean age at study entry was 51.7 years (SD 12.8) in the PsA group, 
and 50.2 years (SD 10.7) in the FM group; the difference was not statistically significant. 
Mean disease duration was 10.2 years (SD 9.3) in the PsA group, and 5.6 years (SD 4.5) 
in the FM group. The differences in the gender ratios and disease duration were highly 
significant (p <0.001) and inherent to the particular conditions. The mean body mass index 
(BMI) was 27.1 (SD 6.1) in the PsA patients and 24.4 (SD 3.6) in the FM patients (p = 
0.05). Finally, the 30 PsA (13 females and 17 males) and 30 FM patients (all females) of 
the PDUS cohort had comparable mean age (51.612.2 and 51.211.6, respectively) and 
BMI (25.25.3 and 24.93.7, respectively). 
Table 1 shows the clinical characteristics of the study population. As laid down by the 
protocol, none of the FM subjects had PsA or reported any personal or familial history of 
psoriasis. The mean PASI of the PsA patients was only 2.2 (SD 3.1), indicating good 
control of the skin disease. It is worth noting that 41 PsA patients (15.4%) had arthritis sine 
psoriasis. The predominant pattern of articular involvement in the PsA group was 
polyarthritis (150 patients, 56.8%), followed by oligoarthritis (67, 25.4%), axial involvement 
(30, 11.4%), and enthesitis (17, 6.4%). Two patients had missing subgroup classification 
data. Although almost 57% of the PsA patients were in the polyarthritis subset, the mean 
number of (SD) of swollen joints was only 1.8 (3.5). This discrepancy was probably due to 
the fact that virtually all of these patients were taking disease-modifying drugs and that 
about 30% of them were on TNF- blockers. 
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A number of the significant clinical differences between the two groups shown in Table 1 
were expected and due to the intrinsic nature of the two diseases, but some were not. The 
proportion of patients with IBP and tenderness in the sacroiliac joints upon examination 
was similar in the two groups (about 35-40%), whereas the mean MASES was significantly 
higher in the FM patients. One hundred and sixteen PsA patients (43.6%) reported a 
“good” or “very good” response to NSAIDs therapy, against only 13 of the FM patients 
(3.1%) (p<0.001). 
About 40% of the PsA patients complained of extra-articular pain, but only 6.9% had at 
least eleven tender points upon examination. All of the somatic manifestations were 
significantly much more frequent in the FM patients, but as many as about 66% of the PsA 
patients complained of fatigue. 
As the MASES scores closely correlated with the tender point counts (r = 0.688, p<0.001), 
we investigated whether any of the MASES sites were significantly more frequently 
involved in one condition than the other. Univariate analysis showed that all of the sites 
were significantly more frequently involved in FM, but only the seventh rib and the anterior 
superior iliac spine remained significantly associated with FM at multivariate analysis (p 
<0.001). 
The PDUS evaluation showed inflammatory changes (tendon hypoechogenicity, bony 
erosions, and PD signal in the enthesis) in 21 (70%) PsA patients but also in seven 
(21.3%) FM patients. Bony erosions were the only findings absolutely specific for PsA, but 
they were seen in only six (20%) patients. Ten entheseal sites per patient were examined 
both clinically and by PDUS. This comparison yielded very different results in the two 
conditions. Of the 300 examined sites in PsA patients, 25 were clinically positive and 
PDUS negative, 39 clinically negative and PDUS positive, and 18 positive by both 
methods. In FM patients, 112 sites were clinically positive and PDUS negative, 8 clinically 
negative and PDUS positive, and only 4 positive by both methods. Interestingly enough, in 
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these patients epicondyles and great trocanthers were responsible for almost all of clinical 
entheseal involvement; only four Achilles tendons, five quadriceps tendons, and no plantar 
fascia insertions were positive on clinical examination. 
Given its efficacy in PsA, anti-tumour necrosis factor- (TNF) therapy may have been a 
confounder in 33% of the PsA patients. However, as extra-articular pain was similarly 
frequent in the patients on or off this therapy (44.9% and 39.6%), its impact on the clinical 
findings could have been limited. 
Table 2 shows the laboratory findings and the mean results of the questionnaires and 
VAS. As expected, inflammatory indices were significantly higher in the PsA patients. The 
mean FIQ values were significantly higher in the FM patients, whereas the mean values of 
the two disability indices (HAQ and LDQ) were similar in the two groups. 
As all of the somatic symptoms were significantly more frequent in the FM patients, we 
used logistic regression analysis to establish which were independently predictive of FM. 
The results showed that sleep disturbances, irritable bowel syndrome, Raynaud’s 
phenomenon, and headache had the strongest ORs for FM (Tab. 3), whereas fatigue, 
stiffness, depression and anxiety did not discriminate between PsA and FM. 
The ROC curves (Fig. 1) showed that the most sensitive and specific predictors of a 
diagnosis of FM was the presence of at least six somatic symptoms (sensitivity 93% and 
specificity 82%) and at least eight tender points (sensitivity 93% and specificity 82%), and 
a MASES score of 3 (sensitivity 68% and specificity 72%). The number of patients 
satisfying the cut-off values derived from the ROC analysis of each variable was obviously 
much higher in the FM group. However, 17.6% PsA patients had at least eight tender 
points (as against 92.7% of FM patients), 14.1% had at least six FM-related symptoms (as 
against 92.7% of FM patients), and 28.2% had a MASES score of 3 (as against 67.7% of 
FM patients). 
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The logistic regression model, which included all of the variables that were common to the 
two conditions and most relevant to their differential diagnosis, showed that number of 
somatic symptoms and number of tender points was independent predictors of FM (Table 
4). Using the cut-off values identified by the ROC analysis the same model yielded an OR 
of 14.73 (CI 3.61-60.09) for 6 somatic symptoms and 30.55 (CI 5.04-185.39) for 8 
tender points,. 
Finally, the analysis of the 17 patients of the “enthesitis predominant” subgroup, of the 67 
with oligoarthritis, and of the 41 without psoriasis did not yield significant differences with 
the PsA group as a whole, with the exception of “extra-articular pain”, which was more 
frequent in the enthesitic subgroup (60% vs. 40.2%). 
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DISCUSSION 
The main aim of this study was to identify the clinical features that can help to distinguish 
between PsA and FM. Although oligo-polyarthritis is the most common articular 
manifestation in PsA, extra-articular pain is frequent and its origin may be difficult to 
establish as it may be caused by enthesitis (a common feature of PsA) but also by FM. 
The prevalence of FM among PsA patients is unknown, although a study published many 
years ago [15] found tenderness in ten or more fibrositic sites in 24% of PsA patients as 
against 57% of patients with rheumatoid arthritis. In the absence of objective signs of 
inflammation at entheseal sites, it may be difficult to distinguish enthesitic and fibromyalgic 
pain clinically. The symptom overlap between the two conditions may lead to even more 
difficulty in patients with undiagnosed PsA characterized by enthesitis alone. Only about 
6% of the PsA patients in our study population presented this disease pattern. The 
analysis of these patients, as well as of those with oligoarthritis and those without 
psoriasis, yielded results similar to those of the whole PsA population. With the limitation of 
the low number of patients, this finding might indicate that “enthesitis predominant” is a 
definite PsA subgroup, distinguishable from FM. 
The results of this study suggest that the presence of >6 somatic manifestations and >8 
tender points indicate the greatest probability of having FM. Raynaud’s phenomenon, 
sleep disturbances, irritable bowel syndrome and headache were the somatic disturbances 
with the highest individual ORs for FM, whereas fatigue, stiffness, anxiety and depression 
were not significantly associated with FM at multivariate analysis. In particular, fatigue (a 
typical symptom of FM) was also present in the majority of PsA patients (about 66%), a 
finding that is consistent with previously published data [16]. 
Although the presence of 8 tender points and 6 FM-related symptoms were strongly 
predictive of FM, they were respectively recorded in about 14% and 18% of our PsA 
patients. These may have been patients with secondary FM, but the collected data did not 
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allow this distinction. However, only about 7% of the PsA patients reached the cut-off point 
of 11 positive tender points considered diagnostic of FM by the 1990 ACR criteria [3]. 
It has been previously found that FM patients respond poorly to NSAIDs, and this has 
been used as a means of differentiating FM and spondyloarthritic-enthesitic patients [17]. 
However, as many as about 66% of our PsA patients did not respond well to NSAIDs and 
lack of response to NSAIDs was not independently associated with FM at multivariate 
analysis. Therefore, the discriminating usefulness of this parameter by itself seems to be 
limited. 
Our findings showed that tender points and entheseal sites overlapped so much that 
median MASES values were significantly higher in the FM patients. The involvement of 
three or more entheseal sites proved to be the most sensitive and specific cut-off point for 
a diagnosis of FM, but significance was lost at multivariate analysis and about 30% of our 
PsA patients had three or more involved entheseal sites. Taken together, these data 
suggest that tenderness at entheseal sites by itself is not at all useful in distinguishing 
between the two conditions. We did not investigate swelling at these sites, which should 
be quite specific, but probably poorly sensitive, for inflammation. As the PDUS study, 
which was performed in a small cohort of patients (30 PsA and 30 FM), evaluated the main 
entheses of the limbs, of the sites included in the MASES only the Achilles tendons were 
investigated by this imaging technique. In contrast to the clinical findings, the PDUS 
evaluation showed that inflammatory changes in the entheseal sites were much more 
frequent in PsA patients than in FM patients. However, as these changes were also found 
in about 21% of the FM patients, they were not highy specific for PsA. The relatively low 
concordance rate between clinical and PDUS enthesitis in the PsA patients was an 
intriguing finding. Of the 82 sites involved according to at least one of the two methods, 
only 18 (22%) were positive at both. This result raises the issue of the definition of 
enthesitis. In this study it was defined as tenderness upon application of pressure at 
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enthesis enough to blanch the examining nail. Using this method, in the PDUS cohort 43 
sites were positive but the 39 sites with inflammatory changes at PDUS were clinically 
silent. This finding suggests that enthesitis could be often asymptomatic but it also indicate 
that a more reliable definition of enthesitis is needed. Finally, in the FM patients of the 
PDUS cohort, on clinical examination some enthesis (epicondyles and great trocanthers) 
were involved in a high percentage of cases, whereas other entheses (quadriceps tendon, 
Achilles tendons, plantar fascia insertion) showed almost no involvement. This finding 
suggests that methods more comprehensive than MASES could be more useful to 
distinguish PsA and FM patients. However, in the whole study population Achilles tendon 
was not significantly more frequent in PsA patients, due to the infrequent involvement of 
this tendon in these patients (low sensitivity). 
The mean self-assessed pain and FIQ scores were higher in the FM patients, but their 
ORs were not significant at multivariate analysis. The mean values of the two disability 
indices (HAQ and LDQ) and the patients’ evaluation of general health were similar in the 
two groups and therefore do not distinguish the two conditions. IBP and tenderness in the 
sacroiliac joints were similarly frequent in the two groups; however, it is worth mentioning 
that sacro-iliac joint examinations are not consistently capable of identifying inflammatory 
involvement [18]. Finally, inflammatory joint involvement and abnormal acute-phase 
reactant values were absent or very rare in the FM patients but, as they are intrinsic 
characteristics of PsA, they cannot be used to identify which patients with known PsA also 
have FM. 
To the best of our knowledge, this is the first study investigating how to differentiate FM 
and PsA patients. However, it is interesting to note that a small cohort study of only 33 
patients [17] with extra-articular pain found that the significant differences in the clinical 
characteristics of SpAs and FM were similar to those found by us between PsA and FM.  
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In brief, our findings seem to indicate that somatic symptoms and tender point counts 
could be used in clinical practice to determine whether PsA patients have associated FM 
when they complain of extra-articular pain. In this situation, the likelihood of having FM is 
proportional to the number of positive features, and is very high in the case of 8 tender 
points and 6 FM-related symptoms. These findings may also be extended to help 
diagnose patients with psoriasis or undifferentiated SpAs with extra-articular pain, but this 
possibility needs to be evaluated by specifically-oriented studies. 
This study has some limitations. The PsA group included patients with any PsA clinical 
pattern, not only those with had polyenthesitis; the extent to which our findings apply to 
these patients needs to be evaluated further. As mean disease duration in the PsA group 
was quite long, the results can only considered valid for patients with long-standing 
disease; patients with early PsA might be different. Tender point evaluations are highly 
examiner-dependent and subject to considerable inter-observer variability. We tried to 
minimise this by providing a DVD showing how to make the tender point count but did not 
check the way the examination was actually conducted; however, as this was a multicentre 
study, the large number of examiners may have compensated for the variability. Finally, as 
about one third of the PsA patients were taking anti-TNF therapy, all of the inflammatory 
features of these patients, including enthesitis and joint swelling, were profoundly modified. 
Obviously the results of this study were biased by this fact, but in a way consistent with 
what happens in daily practice. 
In conclusion, it may be difficult to distinguish polyenthesitis and FM in patients with PsA 
and extra-articular pain, but our findings show that some of the clinical data that can be 
easily collected during a standard rheumatological visit can provide a differential diagnosis. 
These findings should be tested in a control population of PsA patients. PDUS and/or 
magnetic resonance of the entheses might provide further data on this topic [19, 20]. 
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TABLES AND FIGURES 
 
TABLE 1. Clinical characteristics of the study population (n = 358) 
Clinical Feature of PsA PsA (266 pts) FM (120 pts) P value 
Psoriasis, n. (%) 207 (77.8) 0 (0) <0.001 
Personal history of psoriasis, n. (%) 225 (85.6) 0 (0) <0.001 
Familial history of psoriasis, n. (%) 124 (46.6) 0 (0) <0.001 
Tender joint couns mean (SD) 5.0 (6.9) 0.1 (0.9) <0.001 
Swollen joint coumt, mean (SD) 1.8 (3.5) 0.0 (0.0) <0.001 
Damaged joint count, mean (SD) 1.2 (3.3) 0.0 (0.0) <0.001 
MASES, mean (SD) 1.9 (2.4) 4.2 (3.8) <0.001 
Dactylitis, n. (%) 101 (38.0) 0 (0) <0.001 
IBP, n. (%) 115 (43.2) 43 (35.8) 0.17 
Tenderness in the sacroiliac joints, n. (%) 96 (36.1) 45 (37.5) 0.79 
Good or very good response to NSAIDs, n. 116 (43.6) 13 (10.8) <0.001 
Anti-TNF- therapy, n. (%) 89 (33.5) 0 (0) <0.001 
Clinical Features of FM    
Extra-articular pain, n. (%) 107 (40.2) 84 (70) <0.001 
Tender point count, mean (SD) 3.5 (3.9) 12.3 (3.9) <0.001 
Fatigue, n. (%) 175 (65.8) 120 (100) <0.001 
Headache, n. (%) 73 (27.4) 98 (81.7) <0.001 
Irritable bowel syndrome, n. (%) 56 (21.1) 100 (83.3) <0.001 
Sleep disturbances, n. pts (%) 94 (35.3) 110 (94.0) <0.001 
Paresthesias, n. (%) 94 (35.3) 102 (85.0) <0.001 
Stiffness, n. (%) 139 (52.3) 107 (89.2) <0.001 
Depression, n. (%) 65 (24.4) 80 (66.7) <0.001 
Anxiety, n (%) 124 (46.6) 93 (77.5) <0.001 
Raynaud’s phenomenon, n. (%) 13 (4.9) 68 (56.7) <0.001 
 
SD = standard deviation; F = female; M = male; IBP = inflammatory back pain  
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TABLE 2. Laboratory and questionnaire results 
 PsA (266 pts) FM (120 pts) P value 
Mean ESR, mm/h (SD) 19.2 (15.8) 11.3 (6.8) <0.001 
Mean CRP, mg/dL (SD) 1.5 (2.7) 0.3 (0.4) <0.001 
ESR >15 mm/h, n. (%) 118 (45.4) 27 (23.3) <0.001 
CPR >1 mg/dl, n. (%) 90 (35.0) 4 (3.5) <0.001 
VAS pain score, mean (SD) 38.3 (24.1) 58.1 (21.3) <0.001 
HAQ score, mean (SD) 0.7 (0.6) 0.7 (0.5) 0.92 
VAS general health score, mean 
(SD) 
55.4 (22.7) 58.7 (19.3) 0.14 
FIQ score, mean (SD) 32.9 (21.0) 57.9 (20.0) <0.001 
LDQ score, mean (SD) 0.9 (2.7) 1.7 (3.3) 0.43 
 
ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; VAS = visual analogue 
scale; HAQ = Health Assessment Questionnaire; FIQ = Fibromyalgia Impact 
Questionnaire; LDQ = Leeds Disability Questionnaire 
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TABLE 3. Logistic regression of somatic symptoms indicating a risk of FM 
Symptoms OR 95% CI P value 
Extra-articular pain (yes vs no) 3.4 1.3-9.1 0.01 
Fatigue (yes vs no) 1.2 0.4-2.2 0.67 
Headache (yes vs no) 4.7 1.9-11.7 0.001 
Irritable bowel syndrome (yes vs no) 9.8 3.9-24.4 <0.001 
Sleep disturbances (yes vs no) 6.9 2.1-22.5 0.001 
Paresthesias (yes vs no) 3.0 1.1-8.0 0.02 
Stiffness (yes vs no) 2.3 0.8-7.0 0.13 
Depression (yes vs no) 0.7 0.3-1.9 0.56 
Anxiety (yes vs no) 0.5 0.2-1.6 0.28 
Raynaud’s phenomenon (yes vs no) 8.3 3.0-22.7 <0.001 
 
OR = odds ratio; 95% CI = 95% confidence interval 
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TABLE 4. Multivariate logistic regression including the main variables possibly associated 
with FM, and shared by both conditions 
Feature OR 95% CI P value 
Female gender 0.23 0.02-2.54 0.23 
FIQ score 0.98 0.94-1.02 0.26 
Pain score (VAS) 0.99 0.95-1.02 0.51 
Somatic symptoms 3.25 1.96-5.38 0.000 
MASES  0.78 0.63-0.98 0.03 
Tender points 1.63 1.31-2.03 0.000 
No response to NSAIDs 1.99 0.40-9.87 0.39 
 
OR = odds Ratio; 95% CI = 95% confidence interval;VAS = visual analogue scale; FIQ = 
Fibromyalgia Impact Questionnaire; MASES = Maastricht Ankylosing Spondylitis Enthesitis 
Score 
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FIGURE 1 Receiver-operating characteristic curves of sensitivity and specificity of somatic 
symptoms, tender point count, and Maastricht Ankylosing Spondylitis Enthesitis Score 
(MASES; fibromyalgia vs psoriatic arthritis). 
Panel A. Somatic symptoms, area under the curve (AUC) 0.95, 95% CI 0.93–0.97, p 
<0.001. 
Panel B. Tender point count, AUC 0.92, 95% CI 0.9–0.95, p < 0.001. 
Panel C. MASES, AUC 0.74, 95% CI 0.68–0.8, p < 0.001. 
